Taking both qRT–PCR and IHC results into account, CLDN6 expression was detected in 50% of 12 GCT patients, 25% of four MRT patients and 53% of 19 WT patients (Supplementary Table S1). This evidence concerns the gene CLDN6 and granular cell tumor.